<DOC>
	<DOC>NCT00320541</DOC>
	<brief_summary>This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer</brief_summary>
	<brief_title>A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Females diagnosed with breast cancer and the cancer has spread to distant areas of the breast or organs. Must be able to measure the disease by specific medical parameters May have received breast cancer treatment in the early stage of the disease May be restricted in physically strenuous activity but able to carry out light work. Must have adequate organ function as seen in blood test results. Exclusion Criteria: Cancer that has spread to the brain. Unstable heart problems Unstable high blood pressure. Breast cancer treatment after the disease has considered to spread to other areas or organs. Unable to agree with the requirements of the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer of Breast</keyword>
	<keyword>Cancer of the breast</keyword>
	<keyword>Breast Neoplasms</keyword>
</DOC>